



05-25-04

IFW

PHA 4265.1 (01258/1/US)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Diane T. Stephenson et al.

Art Unit 1614

Serial No. 10/776,744

Filed February 11, 2004

Confirmation No. 3606

For COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND
AN AMPHETAMINE FOR THE TREATMENT OF REDUCED BLOOD FLOW TO
THE CENTRAL NERVOUS SYSTEM

May 24, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT


In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. In accordance with the OG notice of August 5, 2003 partially waiving the requirements of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S. patent documents are not supplied. Applicant submits herewith copies of the foreign patent documents and literature references.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R. §1.97(b) in that applicants believe that it is being filed prior to the mailing date of the first Office action on the merits. Accordingly, neither a statement nor fee under 37 C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the

PHA 4265.1 (01258/1/US)
PATENT

date of mailing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge any required fees regarding this Information Disclosure Statement to Deposit Account No. 19-1345.


Respectfully submitted,

A handwritten signature in black ink, appearing to be 'EJH', written over the text 'Respectfully submitted,'.

Edward J. Hejlek, Reg. No. 31,525
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

EJH/cms

Express Mail Label No. EV 416452684 US

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) 				Application Number	10/776,744
				Filing Date	February 11, 2004
				Confirmation Number	3606
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	3	Attorney Docket No.	PHA 4265.1 (01383/1/US)


U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	1	5,466,823		Talley et al	11/14/1995		
	2	5,521,207		Graneto	05/28/1996		
	3	5,633,272		Talley et al	05/27/1997		
	4	5,932,598		Talley et al	08/03/1999		
	5	6,034,256		Carter et al	03/07/2000		
	6	6,077,850		Carter et al	06/20/2000		
FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	7	WO	98/03484	A1	Merck Frosst Canada Inc.	01/29/1998	
	8	WO	00/24719	A1	Abbott Laboratories	05/04/2000	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/776,744
				Filing Date	February 11, 2004
				Confirmation Number	3606
				First Named Inventor	Diane T. Stephenson
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	3	Attorney Docket No.	PHA 4265.1 (01383/1/US)

OTHER ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	9	BOYESON et al., "Intraventricular Norepinephrine Facilitates Motor Recovery Following Sensorimotor Cortex Injury", Pharmacology Biochemistry and Behavior, 1990, 35: 497-501		
	10	CHEUNG et al, "Cyclooxygenase-1 Gene Knockout Does Not Alter Middle Cerebral Artery Occlusion in a Mouse Stroke Model", Neuroscience Letters, 2002, 330(1): 57-60		
	11	CRISOSTOMO et al, "Evidence that Amphetamine with Physical Therapy Promotes Recovery of Motor Function in Stroke Patients", Annals of Neurology, 1988, 23(1): 94-7		
	12	DHILLON et al., "Amphetamine Administration Improves Neurochemical Outcome of Lateral Fluid Percussion Brain Injury in the Rat", Brain Research, 1998, 304: 231-237		
	13	DIETRICH et al, "Influence of Amphetamine Treatment on Somatosensory Function of the Normal and Infarcted Rat Brain", Stroke, 1990, 21(11Suppl): III147-50		
	14	FEENEY et al, "Amphetamine, Haloperidol, and Experience Interact to Affect Rate of Recovery After Motor Cortex Injury", Science, 1982, 217: 855-857		
	15	FLANAGAN, "Psychostimulant Treatment of Stroke and Brain Injury", CNS Spectrums, 2000, 5(3): 59-69		
	16	GIERSE et al, "Expression and Selective Inhibition of the Constitutive and Inducible Forms of Human Cyclo-oxygenase", Biochemical Journal, 1995, 305: 479-84		
	17	GRADE et al, "Methylphenidate in Early Poststroke Recovery: A Double-blind, Placebo-controlled Study", Archives of Physical Medicine and Rehabilitation, 1998, 79(9): 1047-1050		
	18	HOVDA et al, "Amphetamine with Experience Promotes Recovery of Locomotor Function After Unilateral Frontal Cortex Injury in the Cat", Brain Research, 1984, 298:358-361		
	19	IADECOLA et al, "Cerebral Ischemia and Inflammation", Current Opinion in Neurology, 2001, 14(1): 89-94		


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/776,744	
			Filing Date	February 11, 2004	
			Confirmation Number	3606	
			First Named Inventor	Diane T. Stephenson	
			Group Art Unit	1614	
			Examiner Name		
Sheet	3	of	3	Attorney Docket No.	PHA 4265.1 (01383/1/US)



	20	IADECOLA et al, "Reduced Susceptibility to Ischemic Brain Injury and N-methyl-D-aspartate-mediated Neurotoxicity in Cyclooxygenase-2 Deficient Mice", PNAS, 2001, 98(3): 1294-1299	
	21	IADECOLA et al, "Molecular Pathology of Cerebral Ischemia: Delayed Gene Expression and Strategies for Neuroprotection", Frontiers of Neurology, 1997, 835: 203-17	
	22	LAPCHAK et al, "Neuroprotection by the Selective Cyclooxygenase-2 Inhibitor SC-236 Results in Improvements in Behavioral Deficits Induced by Reversible Spinal Cord Ischemia", 2001, Stroke, 32: 1220-1225	
	23	NAGAYAMA et al, "The Cyclooxygenase-2 Inhibitor NS-398 Ameliorates Ischemic Brain Injury in Wild-Type Mice but not in Mice with Deletion of the Inducible Nitric Oxide Synthase Gene", Journal of Cerebral Blood Flow & Metabolism, 1999, 19(11): 1213-1219	
	24	NOGAWA et al, "Cyclo-Oxygenase-2 Gene Expression in Neurons Contributes to Ischemic Brain Damage", Journal of Neuroscience, 1997, 17: 2746-2755	
	25	SAIRANEN et al, "Cyclooxygenase-2 is Induced Globally in Infarcted Human Brain", Annals of Neurology, 1998, 43(6): 738-47	
	26	STROEMER et al, "Enhanced Neocortical Neural Sprouting, Synaptogenesis and Behavioral Recovery with D-Amphetamine Therapy After Neocortical Infarction in Rats", 1998, Stroke, 29: 2381-2395	
	27	SUTTON et al, "Noradrenergic Agonists and Antagonists Affect Recovery and Maintenance of Beam Walking Ability After Sensorimotor Cortex Ablation in the Rat", Restorative Neurology and Neuroscience, 1992, 4: 1-11	
	28	TANAKA et al, "Post-Ischemic Administration of the Acetylcholinesterase Inhibitor ENA-713 Prevents Delayed Neuronal Death in the Gerbil Hippocampus", Neurochemical Research, 1995, 20(6): 663-667	
	29	TURSKI et al, "ZK200775: A Phosphonate Quinoxalinedione AMPA Antagonist for Neuroprotection in Stroke and Trauma", PNAS USA, 1998, 95: 10960-10965	
	30	WALKER-BATSON et al, "Amphetamine Paired with Physical Therapy Accelerates Motor Recovery After Stroke", Stroke - A Journal of Cerebral Circulation, 1995, 26: 2254-2259	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.